Free Trial

VolitionRx Q1 2024 Earnings Report

VolitionRx logo
$0.55 -0.02 (-4.13%)
As of 02/21/2025 04:00 PM Eastern

VolitionRx EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

VolitionRx Revenue Results

Actual Revenue
$0.17 million
Expected Revenue
$0.27 million
Beat/Miss
Missed by -$100.00 thousand
YoY Revenue Growth
N/A

VolitionRx Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

VolitionRx Earnings Headlines

Ex-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”
Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. Should you sit on the sideline while this is happening?
See More VolitionRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VolitionRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VolitionRx and other key companies, straight to your email.

About VolitionRx

VolitionRx (NYSE:VNRX), a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

View VolitionRx Profile

More Earnings Resources from MarketBeat